Silva Carla Sousa da, Martinelli Katrini Guidolini, Viana Marlison Wesley Miranda, Soares Deliane Dos Santos, Corrêa Yasmin Garcia Silva, Silva Lucas Lima da, Paula Vanessa Salete de, Rodrigues Luana Lorena Silva, Villar Livia Melo
Programa de Pós-Graduação em Ciências da Saúde, Instituto de Saúde Coletiva, Universidade Federal do Oeste do Pará (UFOPA), Santarém 66075-110, Brazil.
Laboratório de Hepatites Virais, Instituto Oswaldo Cruz (IOC/Fiocruz), Rio de Janeiro 21040-360, Brazil.
Life (Basel). 2024 Jul 11;14(7):869. doi: 10.3390/life14070869.
COVID-19 is a multisystem disease with many clinical manifestations, including liver damage and inflammation. The objective of this study is to analyze inflammation biomarkers in relation to the clinical outcome and respiratory symptoms of COVID-19. This is a retrospective cohort of patients with COVID-19 admitted to the Hospital Regional do Baixo Amazonas from 2020 to 2022. Data were collected from electronic medical records from admission to the 30th day of hospitalization and soon after hospital discharge. A total of 397 patients were included in the study. In the longitudinal follow-up of liver markers, a significant difference was found for AST on day 14, with a higher median in the death group. Among the hematological markers, lymphopenia was observed throughout the follow-up, with the death group having the most altered values. When comparing the evolution of biomarkers in the Non-Invasive Ventilation (NIV) and Invasive Mechanical Ventilation (IMV) groups, AST showed a significant difference only on day 14 and GGT on day 1, being greater in the IMV group, and indirect bilirubin on day 7 being more altered in the NIV group. In conclusion, death during hospitalization or a more severe form of COVID-19 was related to significant changes in liver and inflammatory biomarkers.
新型冠状病毒肺炎（COVID-19）是一种具有多种临床表现的多系统疾病，包括肝损伤和炎症。本研究的目的是分析与COVID-19临床结局和呼吸道症状相关的炎症生物标志物。这是一项对2020年至2022年入住亚马逊下游地区医院的COVID-19患者的回顾性队列研究。数据从入院至住院第30天以及出院后不久的电子病历中收集。共有397名患者纳入研究。在肝脏标志物的纵向随访中，第14天的天门冬氨酸氨基转移酶（AST）有显著差异，死亡组的中位数更高。在血液学标志物中，整个随访过程中均观察到淋巴细胞减少，死亡组的值变化最大。比较无创通气（NIV）组和有创机械通气（IMV）组生物标志物的变化时，AST仅在第14天有显著差异，γ-谷氨酰转移酶（GGT）在第1天有显著差异，IMV组更高，间接胆红素在第7天NIV组变化更大。总之，住院期间死亡或更严重形式的COVID-19与肝脏和炎症生物标志物的显著变化有关。
